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Saudi Journal of Ophthalmology (2012) 26, 115–116EditorialGetting more information from the surgical specimenIn 1821, Antonio Scarpa reported removing a tumor from
the orbit without removing the eye. This publication is
thought to be the first description of surgical treatment of
an optic nerve glioma but there is considerable doubt about
the exact diagnosis. Even though Scarpa was arguably the
most prominent anatomist and surgeon of his day there
was little he could do to learn more about the origin of the
excised tumor except for gross inspection and perhaps dis-
section.1 Surgical specimens removed during the early 19th
century were probably discarded or, in exceptional cases,
put in a glass jar for display in a museum.
Gross description of surgical specimens was the norm
even up to the time of the American Civil War (1861–1865).
The Army Medical Museum (forerunner of the Armed Forces
Institute of Pathology) was founded in 1862 to collect and
catalog specimens, which was of no direct benefit to those
injured. During the last part of the 19th century methods of
fixing tissue (freezing initially and formalin later), creating
tissue sections thin enough to transmit light (paraffin or cel-
loidin embedding and microtome sectioning) and staining
the tissues (red cabbage juice to hematoxylin-eosin) were
developed. And even though microscopes were available
surgical specimens were not routinely evaluated. Part of the
problem was the slow acceptance of the Virchow’s theory
of the cellular basis of disease. Technical problems such as
chromatic and spherical aberration of crude lenses and lack
of adequate illumination also contributed. Most pathologists
of the time only performed autopsies and had no direct con-
tact with the surgeons.
Microscopic descriptions and direct interaction of the
pathologist with the surgeon concerning a specific patient
was the exception rather than a rule at the beginning of
the 20th century. The first surgical pathology laboratory lo-
cated near a surgical suite was not established at the Mayo
Clinic in North America until 1915.2 The histologic charac-
ter of individual tumors could now be linked with clinical
history and follow up information allowing the develop-
ment of grading systems to predict in a general manner
the anticipated behavior of the tumor. This system bene-
fited populations of patients with a specific type of tumor
but the information was not precise enough to predict
the outcome of an individual patient. A patient with optic
nerve glioma could now be told with certainty that the
tumor was in fact a pilocytic astrocytoma but even though
the tumor generally acted in a benign or indolent manner
there was still 5–15% mortality.
Electron microscopy, developed during the 1970s as a
diagnostic tool, was used to look for more precise indications
of outcome. The origins of tumors could be more exactly
determined but the ultimate clinical outcome could not be
established. Electron microscopy was time-consumingPeer review under responsibility
of Saudi Ophthalmological Society,
King Saud University(weeks) and expensive. Diagnostic immunohistochemistry
completely replaced electron microscopy by the early
1990’s. The technique employs specific antibodies directed
against specific cellular components or products. Specific tu-
mor types could be identified with high specificity and sensi-
tivity in hours at a relatively low cost. Even with this
sophisticated technical advance the persons at the greatest
risk for death from optic nerve glioma could not be
identified.3
Molecular diagnostic testing is the next logical step in
obtaining very specific information from surgical specimens
for a particular patient. The understanding of the basic
nature of cancer has evolved quickly over the last two dec-
ades. Cancer originates from ‘‘non-lethal’’ genetic damage
of a single cell. Lethal genetic damage will eliminate a cell
from tissue. However ‘‘non-lethal’’ damage may affect a
cell’s ability to reproduce resulting in uncontrolled growth
of that cell and its cellular progeny (i.e. cancer). It is now
known that cell proliferation is controlled by a series of
proteins (enzymes) located in the cell between the cell sur-
face receptors and the DNA of the cell nucleus. There are
many redundant protein kinase pathways and many feed-
back safe-guards within each pathway. The clinical outcome
may depend on which part of which protein kinase
pathway is abnormal. Now with sophisticated biochemical
procedures, such as polymerase chain reaction (PCR) and
fluorescent in situ hybridization (FISH), damaged control
proteins can be identified allowing the categorization of a
particular tumor with a specific outcome.4
The value of the surgical specimen has evolved. Initially,
only gross description was possible and the specimen was
placed as a curiosity in a glass jar. Technical advances in
tissue processing allowed precise identification of cell type
by light microscopy but only general categorization of
anticipated outcome. In the case of optic nerve glioma,
more sophisticated technical procedures such as electron
microscopy and immunohistochemistry were not able to
provide additional information about outcome. Now with
information about the fundamental molecular nature of
cancer and highly sophisticated techniques abnormal
control proteins can be identified. In the future with this
information the surgeon can offer the patient more reliable
information both about outcome and the use of novel
treatment strategies based on the unique protein abnor-
mality causing the cancer.References
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Neuropathol Exp Neurol 2012;71(1):66–72.From the Editor’s DeskBeginning in 2011, the Saudi Journal of Ophthalmology introduced thematic issues
dedicated to topics such as Oculoplastics, Diabetic Retinopathy, Cornea and Refrac-
tive Surgery, Glaucoma and Cataract. We have received excellent reviews and feed-
back on these issues from the readership. I take this opportunity to thank Drs Imtiaz
Chaudhry, Ahmed Abu El-Asrar, Khalid Tabbara and Jose Morales for their tireless
effort that ensured success in each of these thematic issues.
Continuing with the outstanding response, I am pleased to present our readership
with the Ophthalmic Pathology Update issue. In this issue we focus on the current
topics in pathology. The reader will find cogent articles on various topics with direct
clinical relevance. The guest editor Dr Hind M. Alkatan, Head of Pathology and Lab-
oratory Medicine at King Khaled Eye Specialist Hospital, was instrumental in inviting
authors and coordinating this issue. We thank her for her diligence and effort in devel-
oping this current survey of ophthalmic pathology.
We also thank the authors who willingly accepted the tasks of writing articles de-
spite the myriad commitments of clinics and teaching. To the Reviewers, we thank
them for their time and their expertise in refining the articles. The collection of ex-
perts in the field is directly reflected by the quality of the articles presented in these
issues.
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